Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413350052> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2413350052 endingPage "9" @default.
- W2413350052 startingPage "591" @default.
- W2413350052 abstract "In the treatment of coronary atherosclerotic artery disease (CAD), the mechanisms by which lipid lowering, a proven therapy, produces beneficial clinical effects remain unclear. Moreover, although potential mechanisms of benefit are well known and increasingly applied clinically, there are no conclusive data from clinical trials studying primarily the antiischemic effects of angiotensin-converting enzyme (ACE) inhibition in patients with normal heart function. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) is designed to clarify some of these issues in CAD patients with normal or mildly elevated cholesterol. DESIGN AND OBJECTIVES: SCAT is a three- to five-year, multicentre, randomized, double-blind, placebo controlled, 2 x 2 factorial trial evaluating the effects of cholesterol lowering therapy by simvastatin and/or ACE inhibition by enalapril on anatomic coronary atherosclerosis progression assessed by quantitative coronary angiography in CAD patients with preserved left ventricular function and total cholesterol levels between 4.1 and 6.2 mmol/L.Of 460 patients (age 61 +/- 9 years; 409 males, 51 females) enrolled between June 1991 and July 1995, 230 were randomized to simvastatin and 230 to placebo, and 229 to enalapril and 231 to placebo. Average baseline total cholesterol level was 5.20 +/- 0.61 mmol/L, high density lipoprotein cholesterol was 0.99 +/- 0.25 mmol/L, low density lipoprotein cholesterol was 3.36 +/- 0.57 mmol/L and triglycerides were 1.82 +/- 0.75 mmol/L. The trial will be completed in June 1998.Insights gained from this long term angiographic trial will lead to a better understanding of the mechanisms of benefits of these two treatments, both alone and in combination. Of particular interest is that this trial will be able to examine a suspected beneficial interaction, if present, between these two treatments." @default.
- W2413350052 created "2016-06-24" @default.
- W2413350052 creator A5016716924 @default.
- W2413350052 creator A5017902770 @default.
- W2413350052 creator A5019732435 @default.
- W2413350052 creator A5024045722 @default.
- W2413350052 creator A5037249140 @default.
- W2413350052 creator A5041222213 @default.
- W2413350052 date "1997-06-01" @default.
- W2413350052 modified "2023-09-23" @default.
- W2413350052 title "Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators." @default.
- W2413350052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9215232" @default.
- W2413350052 hasPublicationYear "1997" @default.
- W2413350052 type Work @default.
- W2413350052 sameAs 2413350052 @default.
- W2413350052 citedByCount "5" @default.
- W2413350052 crossrefType "journal-article" @default.
- W2413350052 hasAuthorship W2413350052A5016716924 @default.
- W2413350052 hasAuthorship W2413350052A5017902770 @default.
- W2413350052 hasAuthorship W2413350052A5019732435 @default.
- W2413350052 hasAuthorship W2413350052A5024045722 @default.
- W2413350052 hasAuthorship W2413350052A5037249140 @default.
- W2413350052 hasAuthorship W2413350052A5041222213 @default.
- W2413350052 hasConcept C126322002 @default.
- W2413350052 hasConcept C134018914 @default.
- W2413350052 hasConcept C142724271 @default.
- W2413350052 hasConcept C164705383 @default.
- W2413350052 hasConcept C204787440 @default.
- W2413350052 hasConcept C27016395 @default.
- W2413350052 hasConcept C27081682 @default.
- W2413350052 hasConcept C2775940317 @default.
- W2413350052 hasConcept C2776329913 @default.
- W2413350052 hasConcept C2777482532 @default.
- W2413350052 hasConcept C2778163477 @default.
- W2413350052 hasConcept C2778213512 @default.
- W2413350052 hasConcept C2991716557 @default.
- W2413350052 hasConcept C71924100 @default.
- W2413350052 hasConcept C84393581 @default.
- W2413350052 hasConceptScore W2413350052C126322002 @default.
- W2413350052 hasConceptScore W2413350052C134018914 @default.
- W2413350052 hasConceptScore W2413350052C142724271 @default.
- W2413350052 hasConceptScore W2413350052C164705383 @default.
- W2413350052 hasConceptScore W2413350052C204787440 @default.
- W2413350052 hasConceptScore W2413350052C27016395 @default.
- W2413350052 hasConceptScore W2413350052C27081682 @default.
- W2413350052 hasConceptScore W2413350052C2775940317 @default.
- W2413350052 hasConceptScore W2413350052C2776329913 @default.
- W2413350052 hasConceptScore W2413350052C2777482532 @default.
- W2413350052 hasConceptScore W2413350052C2778163477 @default.
- W2413350052 hasConceptScore W2413350052C2778213512 @default.
- W2413350052 hasConceptScore W2413350052C2991716557 @default.
- W2413350052 hasConceptScore W2413350052C71924100 @default.
- W2413350052 hasConceptScore W2413350052C84393581 @default.
- W2413350052 hasIssue "6" @default.
- W2413350052 hasLocation W24133500521 @default.
- W2413350052 hasOpenAccess W2413350052 @default.
- W2413350052 hasPrimaryLocation W24133500521 @default.
- W2413350052 hasRelatedWork W1963484025 @default.
- W2413350052 hasRelatedWork W1967118287 @default.
- W2413350052 hasRelatedWork W1971472376 @default.
- W2413350052 hasRelatedWork W1975864662 @default.
- W2413350052 hasRelatedWork W2009148223 @default.
- W2413350052 hasRelatedWork W2118279423 @default.
- W2413350052 hasRelatedWork W2170388163 @default.
- W2413350052 hasRelatedWork W2317802089 @default.
- W2413350052 hasRelatedWork W2380571071 @default.
- W2413350052 hasRelatedWork W2413350052 @default.
- W2413350052 hasVolume "13" @default.
- W2413350052 isParatext "false" @default.
- W2413350052 isRetracted "false" @default.
- W2413350052 magId "2413350052" @default.
- W2413350052 workType "article" @default.